Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: An observational study

Onkologie

Volumn 33, Issue 12, 2010, Pages 684-690

  Moehler, Markus ^a   Ababneh, Younes ^a   Verpoort, Karl ^b   Schmidt, Burghard ^b   Musch, Reinhard ^c   Soeling, Ulrike ^b   Maintz, Christoph ^b   Siebler, Jürgen ^d   Schimanski, Carl C ^a   Galle, Peter R ^a   Fahlke, Jörg ^e  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Gemeinschaftspraxis Hamburg ^*  (Germany)

^c Deister Süntel Klinik Bad Münder   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e Universitatsklinik Magdeburg   (Germany)

Author keywords

5 Fluorouracil; Age; Colorectal cancer; Combination therapy; Irinotecan; Metastatic disease

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTICHOLINERGIC SYNDROME; ARTICLE; ASTHENIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLON ADENOCARCINOMA; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; PAIN; PROSPECTIVE STUDY; RECTUM CARCINOMA; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 78649944584     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322208     Document Type: Article

References (22)

1. Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 2004;22:3766-3775.
2. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 2000;343:905-914.
5. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Ruckle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Muller L, Genicot B, Anak O, Nordlinger B: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986. J Clin Oncol 2005;23:4856-4865.
6. Moehler M, Hoffmann T, Zanke C, Hohl H, Burg H, Ehscheid P, Schwindt P, Adami B, Schroeder M, Klein O, Baldus M, Galle PR, Heike M: Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. Anticancer Drugs 2003;14:79-85.
7. Teufel A, Steinmann S, Siebler J, Zanke C, Hohl H, Adami B, Schroeder M, Klein O, Hohler T, Galle PR, Heike M, Moehler M: Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer 2004;4:38.
8. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008;26:2013-2019.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
10. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
11. Boyle P, Leon ME: Epidemiology of colorectal cancer. Br Med Bull 2002;64:1-25.
12. Townsley CA, Selby R, Siu LL: Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005;23:3112-3124.
13. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, O'Connor LC, West DW, Allen ME, Wolf RE, Wright WE: Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003;21:1293-1300.
14. Schrag D, Cramer LD, Bach PB, Begg CB: Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-857.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Francois E, Berdah JF, Chamorey E, Lesbats G, Teissier E, Codoul JF, Badetti JL, Hebert C, Mari V: Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: A phase II study. Cancer Chemother Pharmacol 2008;62:931-936.
17. Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E, Schubert U, Kohne CH: Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: Combined analysis of 2, 691 patients in randomized controlled trials. J Clin Oncol 2008;26:1443-1451.
18. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
19. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
20. Chau I, Norman AR, Cunningham D, Waters JS, Topham C, Middleton G, Hill M, Ross PJ, Katopodis R, Stewart G, Oates JR: Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004;91:1453-1458.
21. Sastre J, Marcuello E, Masutti B, Navarro M, Gil S, Anton A, Abad A, Aranda E, Maurel J, Valladares M, Maestu I, Carrato A, Vicent JM, Diaz-Rubio E: Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005;23:3545-3551.
22. Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulias V: Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial. Oncology 2005;69:384-390.